Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

about

Angiogenesis in human brain tumors: screening of drug response through a patient-specific cell platform for personalized therapy.FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells

P2860

Q55415350-17EA9726-79F5-4338-87C9-43B18F81AF61 Q58749539-9C1EFD6F-FE79-4AF3-B844-4D54B0EDEDA4

P2860

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

Item

http://www.wikidata.org/entity/Q39313983

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@en

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@nl

type

Item

label

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@en

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@nl

prefLabel

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@en

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@nl

P1476

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

@en

P2093

Jennifer Clarke

http://www.w3.org/2001/XMLSchema#string

Saad Ali

http://www.w3.org/2001/XMLSchema#string

Soonmee Cha

http://www.w3.org/2001/XMLSchema#string

Yi Li

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex

Modes of resistance to anti-angiogenic therapy

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Treatment with bevacizumab plus carboplatin for recurrent malignant glioma.

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

P304

1-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.14791/BTRT.2017.5.1.1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28516072

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5433944

http://www.w3.org/2001/XMLSchema#string

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

about

P2860

P2860

Bevacizumab in Recurrent Glioma: Patterns of Treatment Failure and Implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932